Skip to content

Gi bleeding treathment

Comparing the effect of injective pantoprazole and oral Rabeprazol in patients with upper gastrointestinal bleeding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013050713261N1
Enrollment
114
Registered
2013-08-03
Start date
2011-04-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper gibleeding. Gastrointestinal haemorrhage, unspecified

Interventions

Intervention 1: Initial treatment included water and electrolyte balancing and injection of Pantoprazole 80 mg and 8 mg per hour and in 24 hours endoscopy was performed on the patients and in patients
Treatment - Drugs
Initial treatment included water and electrolyte balancing and injection of Pantoprazole 80 mg and 8 mg per hour and in 24 hours endoscopy was performed on the patients and in patients who had active
The second group that consumes edible Rabeprazole 40 mg each 12 hours. For all patient endoscopy done in 2 th days.

Sponsors

Personal
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 100 Years

Inclusion criteria

Inclusion criteria: The patients with upper gastrointestinal bleeding and treated by epinephrine injection who wanted to participate in the study and do not had allergy to the Inclusion criteria: underwent urgent endoscopy within 24 h after presentation, had peptic ulcers in the distal oesophagus, stomach or duodenum, had high-risk stigmata including active bleeding , nonbleeding visible vessels , or adherent clots , and successful haemostasis was achieved with endoscopic injection of epinephrine. Written informed consent was obtained before enrolment. Exclusion criteria: pregnant; did not obtain initial haemostasis with endoscopic injection of epinephrine; did not give written informed consent; had bleeding tendency (platelet count 3 s of normal, CT and BT prolong or were taking anticoagulants); had uraemia ; bleeding gastric cancer.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
No reebleeding. Timepoint: 72h. Method of measurement: patient Symptoms and endoscopy in second 24 h.

Secondary

MeasureTime frame
Hospital stay and mortality and blood transfusion. Timepoint: 72h. Method of measurement: symptoms.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Amir Sarabi

personal

masarabi@ssu.ac.irdrsam_amir@yahoo.com+98 35 1822 4201

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026